Table 2.

The pooled prevalence of suicide ideation in transgender population based on type of TS, and continents

Outcomes	Number of studies	Pooled prevalence %	95% CI		Heterogeneity assessment
			Lower %	Upper %	I square %	Z	P value
Overall prevalence	71	48	42	54	88.53	26.62	< 0.0001
Type of prevalence
Point prevalence	3	39	35	43	86.99	22.09	< 0.0001
Period prevalence	16	45	35	54	89.93	26.33	< 0.0001
Life time prevalence	52	50	42	57	88.43	26.41	< 0.0001
Type of TS
Female to male
Overall	11	51	43	59	93.40	12.28	< 0.0001
Period prevalence	2	40	35	45	93.71	12.22	< 0.0001
Life time prevalence	9	53	44	62	88.90	10.33	< 0.0001
Male to female
Overall	20	44	35	53	97.56	19.21	< 0.0001
Period prevalence	3	47	33	61	80.09	16.00	< 0.0001
Life time prevalence	17	43	33	53	90.88	18.29	< 0.0001
Both
Overall	40	49	41	58	89.60	17.05	< 0.0001
Period prevalence	11	45	33	57	89.68	11.45	< 0.0001
Point prevalence	3	39	35	43	98.88	30.36	< 0.0001
Life time prevalence	26	53	40	65	94.66	12.45	< 0.0001
Continents
Europe
Overall	10	43	39	48	86.44	27.69	< 0.0001
Period prevalence	5	38	35	40	0.00	47.97	0.500
Life time prevalence	5	50	38	62	93.52	11.94	< 0.0001
Asia
Overall	17	53	46	59	95.75	23.67	< 0.0001
Period prevalence	1	23	15	33	-	8.87	< 0.0001
Life time prevalence	16	54	48	61	95.51	24.74	< 0.0001
America
Overall	42	46	37	55	97.99	15.30	< 0.0001
Point prevalence	2	37	30	44	89.03	16.69	< 0.0001
Period prevalence	10	50	37	63	89.43	10.82	< 0.0001
Life time prevalence	30	45	33	58	88.99	11.13	< 0.0001
Australia
Overall	2	71	68	74	88.90	54.59	< 0.0001
Continents
Europe
MTF	4	47	38	55	65.29	16.66	0.0380
FTM	4	46	39	54	73.46	18.85	0.0109
Both	2	35	34	37	88.00	96.18	< 0.0001
Asia
MTF	7	52	39	65	97.26	11.68	< 0.0001
FTM	3	58	47	68	88.09	14.90	< 0.0001
Both	7	50	39	62	95.00	12.63	< 0.0001
America
MTF	9	35	23	48	97.59	8.55	< 0.0001
FTM	4	50	22	77	96.45	4.94	< 0.0001
Both	29	49	38	60	99.68	13.06	< 0.0001
Australia
Both	2	71	68	74	89.04	54.59	0.0089

MTF: male to female; FTM: female to male; TS: transgender; CI: confidence interval